NIKKEI 225
37,631.72 +3.24 (+0.01%) HANG SENG
17,284.54 0.00 (0.00%) CRUDE OIL
83.95 +0.38 (+0.45%) GOLD FUTURES
2,341.20 -1.30 (-0.06%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,288.69 -239.27 (-0.46%)
Pfizer Inc. (PFE)
After hours:
| Previous close | 26.27 |
| Open | 26.27 |
| Bid | 25.39 x 1400 |
| Ask | 25.35 x 2200 |
| Day's range | 25.25 - 26.43 |
| 52-week range | 25.23 - 40.37 |
| Volume | |
| Avg. volume | 42,211,908 |
| Market cap | 148.755B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 70.17 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.68 (6.40%) |
| Ex-dividend date | 25 Jan 2024 |
| 1y target est | N/A |
- Business Wire
Pfizer Declares Second-Quarter 2024 Dividend
NEW YORK, April 24, 2024--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company’s common stock, payable June 14, 2024, to holders of the Common Stock of record at the close of business on May 10, 2024. The second-quarter 2024 cash dividend will be the 342nd consecutive quarterly dividend paid by Pfizer.
- Business Wire
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
NEW YORK, April 22, 2024--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative
- Business Wire
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
NEW YORK, April 11, 2024--Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2024 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 25, 2024. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who attend the virtual-only Annual Meeting will be afforded comparable rights and opportunities to participate as they would at an in-person meeting.
